These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 30656853)

  • 1. CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta-analysis.
    Han L; Liu Y; Xiong H; Hong P
    Brain Behav; 2019 Feb; 9(2):e01215. PubMed ID: 30656853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis.
    Hong P; Wu X; Liu Y
    Clin Neurol Neurosurg; 2017 Mar; 154():74-78. PubMed ID: 28129635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
    Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
    CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis.
    Hou M; Xing H; Cai Y; Li B; Wang X; Li P; Hu X; Chen J
    J Headache Pain; 2017 Dec; 18(1):42. PubMed ID: 28389966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis.
    Deng H; Li GG; Nie H; Feng YY; Guo GY; Guo WL; Tang ZP
    BMC Neurol; 2020 Feb; 20(1):57. PubMed ID: 32061264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis.
    Kokoti L; Drellia K; Papadopoulos D; Mitsikostas DD
    J Neurol; 2020 Apr; 267(4):1158-1170. PubMed ID: 31919565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
    Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
    Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Contextual (Placebo) Effects of CGRP Antibodies for Migraine: Systematic Review and Meta-analysis.
    Forbes RB; McCarron M; Cardwell CR
    Headache; 2020 Sep; 60(8):1542-1557. PubMed ID: 32668023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC; Schwedt TJ
    Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.
    Sevivas H; Fresco P
    Eur J Med Res; 2022 Jun; 27(1):86. PubMed ID: 35659086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
    Zhu Y; Liu Y; Zhao J; Han Q; Liu L; Shen X
    Neurol Sci; 2018 Dec; 39(12):2097-2106. PubMed ID: 30182284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcitonin gene-related peptide antagonism for acute treatment of migraine: a meta-analysis.
    Hong P; Liu Y
    Int J Neurosci; 2017 Jan; 127(1):20-27. PubMed ID: 26728923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of atogepant, a small molecule CGRP receptor antagonist, for the preventive treatment of migraine: a systematic review and meta-analysis.
    Hou M; Luo X; He S; Yang X; Zhang Q; Jin M; Zhang P; Li Y; Bi X; Li J; Cheng C; Xue Q; Xing H; Liu Y
    J Headache Pain; 2024 Jul; 25(1):116. PubMed ID: 39030528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway.
    Zhou Z; Urman R; Gill K; Park AS; Vuvu F; Patel LB; Lu J; Wade RL; Frerichs L; Bensink ME
    J Headache Pain; 2023 Nov; 24(1):153. PubMed ID: 37946113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications.
    Dodick DW
    Cephalalgia; 2019 Mar; 39(3):445-458. PubMed ID: 30661365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
    Yuan H; Spare NM; Silberstein SD
    Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erenumab in the treatment of migraine.
    Jain S; Yuan H; Spare N; Silberstein SD
    Pain Manag; 2018 Nov; 8(6):415-426. PubMed ID: 30235976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale.
    Cohen F; Yuan H; Silberstein SD
    BioDrugs; 2022 May; 36(3):341-358. PubMed ID: 35476215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonspecific oral medications versus anti-calcitonin gene-related peptide monoclonal antibodies for migraine: A systematic review and meta-analysis of randomized controlled trials.
    Robblee J; Hakim SM; Reynolds JM; Monteith TS; Zhang N; Barad M
    Headache; 2024 May; 64(5):547-572. PubMed ID: 38634515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.